Kornimate/medical-research-clean huggingface dataset:
effectiveness of cryotherapy on endodontic pain

Conditions: Post Operative Pain

Summary: this is a randomized , prospective , control trial to assess the effectiveness of intracanal cryotherapy on post operative pain after root canal treatment in patients with symptomatic apical periodontitis

diagnostic procedures to include patients history taking , clinical and radiographic with all findings being recorded in patients . patients diagnosed with symptomatic irreversible pulpitis with symptomatic apical periodontitis. patients will be asked to rate their pre treatment pain on visual analogue scale from 0-10 patients with pain score \<8 will be considered anesthesia and isolation : after administration of local anesthesia , rubber dam application will be done acess cavity : acess will be gained with round bur using air turbune handpiece with copious water cooling working length : a size 10k file will be inserted into the canal to determine the working length with the help of radiograph cleaning and shaping : extirpation of pulp will be done followed by canal preparation with manual and endodontic motor using naocl and edta . final irrigation will be performed using 17% edta and 5.25% naocl patients will be divided into 2 group in control group : final irrigation will be done using 5ml of saline at room temperature in cold group : final irrigation will be done using 5ml of cold saline at 2.5°c the solution will be stored in the refrigerator until use irrigation will be performed for 5 min in both groups using 27 g beveled needle tip inserted 2mm short of wl. obturation ; in both groups , canals will be dried with paper points and obturated using gutta percha cones with zinc oxide eugenol sealer restoration : acces cavity will be restroed with direct composite restoration or high viscosity glass ionomer cement each patient will be given instruction to acess the post operative pain .

Eligibility criteria:
inclusion criteria: * patients with symptomatic irreversible pulpitis and symptomatic apical periodontitis * maxillary or mandibular single rooted teeth * systemically healthy patients * patients having pain score \< 8 exclusion criteria: * patients on preoperative analgesics or antibiotics within past 12 hours * teeth with calcified canals and previously treated teeth * tooth with immature apices or resorption * patients allergic to local anesthesia * pregnant or lactating mothers * patients who are immunocompromised .
noninvasive ventilation and thoracic-abdominal kinematics in heart failure patients

Conditions: Heart Failure

Summary: introduction: noninvasive ventilation (niv) has been used to minimize such impairment and increasing ventilator reserve in individuals with heart failure. aim: to analyze thoracoabdominal kinematics (tk) in individuals with hf associated to cardiomegaly after using niv. methods: a randomized crossover clinical trial with allocation consisted of two experimental phases: niv and control, 7 days apart of each other. during niv phase, 30 minutes of bi-level ventilation was performed. any type of ventilator support was offered during control phase. optoeletronic plethismography was performed to asses tk.


Eligibility criteria:
inclusion criteria: * body mass index (bmi) \<30 kg/m2 * functional class ii-iii according to the new york heart association * of the echocardiogram últiimos 6 months showing ejection fraction (lvef) ≤ 45%, * últiimos echocardiogram of six months showing cardiac hypertrophy (left ventricular diastolic diameter (lvdd)\> 55mm, diameter systolic left ventricular (lvsd)\> 45mm ), * (optimized from the point of view of drug, * clinical stability. exclusion criteria: * unstable angina, myocardial infarction or heart surgery three months before the beginning of the research, * chronic orthopedic, infectious or metabolic diseases, * fev1/fvc \<70% predicted characterizing obstructive respiratory disorder; * active smokers; * limitation on the use of niv: claustrophobia, inability to remain with their mouths closed, abdominal distention, hemodynamic instability, heart rate (hr) \<60 bpm, recent trauma, nausea and vomiting face.
sensitivity and specificity of aridol challenge for a diagnosis of asthma by a specialist pulmonologist

Conditions: Asthma

Summary: the purpose of this study is to estimate the sensitivity, specificity and positive and negative predictive values of a positive aridol challenge with respect to a specialist pulmonologist diagnosis of asthma in corticosteroid naive subjects with asthma-like symptoms and no previous diagnosis of asthma. the comparator is methacholine provocation


Eligibility criteria:
inclusion criteria: * informed consent * provisional or possible asthma diagnosis * fev1 at least 70% of predicted at inclusion exclusion criteria: * contraindications for bronchial provocation challenge or spirometry * respiratory tract infection within previous 6 weeks * significant co-morbidity * \> 10 pack year smoking history * other lung diseases * pregnancy, lactation

Keywords: asthma airway hyperresponsiveness dry powder mannitol inhalation methacholine
hormone evaluation in artificial reproductive technology

Conditions: Female Infertility

Summary: the aim is to be able to predict the hormonal response according to gonadotropin receptor genotype and hormone type used for treatment of women undergoing in vitro fertilization or egg donation. outcome will be measured as pregnancy success, live born babies and unwanted side effects.

women undergoing in vitro fertilization receive high doses of the gonadotropins follicle stimulating hormone (fsh) and human chorionic gonadotropin (hcg), which is acting as luteinizing hormone (lh) for stimulation of the ovaries in order to obtain a high number of eggs. there are however marked individual differences in the hormonal response, ranging from lack of increased egg maturation to hyper stimulation. the hypothesis is that genetic variants in the gonadotropin receptors (lh and fsh receptors), are influencing the outcome. this assumption is supported by a recent study on more than 600 women undergoing in vitro fertilization, demonstrating that whereas only 10% of women with asparagine in both genes (fshr n680s and lhr n312s) became pregnant, 40% of those with serine did (lindgren i et al. hum repr 2016; 3:672-83). most (90%) of the women were treated with rfsh (recombinant). however, of the 10% asparagine carriers who actually became pregnant, most if not all, were treated with menotropin - a urine derivated compound (menopur, ferring), which contains both lh and fsh. this finding was not stressed in the manuscript as it could have been due to chance because of the small number of women treated with menotropin. the objective is therefore to perform a prospective randomized study regarding efficacy of treatment in the first and second in vitro fertilization trial with rfsh and menotropin, respectively, genotype taken into account. in total 890 women, 445 in poznan, poland and 445 in malmö, sweden, with unexplained infertility or a male or tubal factor indication for treatment will be invited to participate in the study. at first appointment, information is provided and informed consent retrieved. two blood samples are drawn and stored at -20°c; one for subsequent genotyping and one for anti mullerian hormone measurement. the succeeding treatment is according to normal procedures at respective clinic.

Eligibility criteria:
inclusion criteria: * normal ovulatory cycles 26-32 days * first and second ivf treatment * indication for ivf is male factor, tubal factor or unexplained infertility * medical indication for ivf; \>12 months unprotected intercourse exclusion criteria: * anti müllerian hormone \ 12 * endometriosis * polycystic ovarian syndrome * pre ovarian failure * smoking * male age more than 56.

Keywords: gonadotropin receptor assisted reproduction
a study to evaluate the efficacy and safety of taldefgrobep alfa in participants with spinal muscular atrophy

Conditions: Spinal Muscular Atrophy; Neuromuscular Diseases; SMA

Summary: this trial will study the efficacy and safety of taldefgrobep alfa as an adjunctive therapy for participants who are already taking a stable dose of nusinersen and/or risdiplam and/or have a history of onasemnogene abeparvovec, compared to placebo.

myostatin is a negative regulator of muscle growth. blocking myostatin activity has been shown to increase muscle size and function. taldefgrobep alfa directly blocks myostatin activity and was well tolerated in other clinical studies. in combination with medications that increase the amount of smn protein in the body, taldefgrobep alfa has the potential to further improve motor function and clinical measures for people living with sma.

Eligibility criteria:
key inclusion criteria: * spinal muscular atrophy confirmed by genetic diagnosis of 5q-autosomal recessive sma as well as smn2 copy number * ambulant or non-ambulant * treated with an sma disease-modifying therapy and anticipated to remain on that same treatment regimen and dose throughout the trial including nusinersen and/or risdiplam and/or a history of onasemnogene abeparvovec key exclusion criteria: * cannot have previously taken anti-myostatin therapies * must weigh at least 15kg * respiratory insufficiency, defined by the medical necessity for invasive or non-invasive ventilation for daytime treatment while awake (use overnight or during daytime naps is acceptable) * history of spinal fusion within 6 months of screening. magec rod nonsurgical adjustments are allowed during the study * presence of an implanted shunt for the drainage of csf or an implanted central nervous system (cns) catheter
digital addiction among university students

Conditions: Internet Addiction; University Student

Summary: the aim of this study is to contribute to our understanding of digital media addiction by investigating the prevalence of digital addiction among university students and examining the relationship between variables such as body awareness, physical activity levels, hand grip strength, upper extremity function and pain-dash, quality of life, depression, stress, anxiety, sleep quality, and cognitive levels and digital addiction.

after recording the demographic information of all individuals participating in the study, screen addiction, bmi, body awareness, physical activity levels, handgrip strength, upper extremity pain and function and pain-dash, quality of life, depression, stress, anxiety, sleep quality, cognitive levels will be evaluated. individuals will be asked to fill out self-report questionnaires.

Eligibility criteria:
inclusion criteria: * university students aged 18 and over * those who have been using smartphones for more than a year exclusion criteria: * people under the age of 18, * those diagnosed by a doctor with any musculoskeletal, rheumatic, neurological, cardiovascular system diseases or diagnosed with a mental disorder, sleep disorder such as narcolepsy or addiction to alcohol, substances, etc. * those with any history of injury or surgery in the upper extremity
evaluation of outcomes of robotics rehabilitation in cerebral palsy

Conditions: Cerebral Palsy; Gait Disorders, Neurologic

Summary: the use of robotic devices in rehabilitation programs can improve walking patterns by reorganizing joint kinematics. this study aims to quantify the effects of a rehabilitation program supported by the lokomat (hocoma) robotic device on walking in children and young people with movement disorders, considering different levels of impairment.

cerebral palsy is one of the most common neuromotor disorders in pediatric age, characterized by permanent movement and posture impairments, often affecting walking. in recent decades, advancements in robotics have revolutionized rehabilitation. studies have shown that combining conventional physiotherapy with robotic rehabilitation tools offers greater benefits in patient recovery. at the irccs eugenio medea, a robotic rehabilitation program using the lokomat (hocoma) has been implemented for several years to improve walking in children and young people with walking disorders. the investigators hypothesize that robotic devices can enhance walking ability (e.g., speed, stride length) and reorganize joint kinematics. this study aims to quantify the effects of this treatment based on the level of impairment.

Eligibility criteria:
inclusion criteria: * diagnosis of cp; * able to walk independently with or without assistance exclusion criteria: * presence of behavioral problems; * presence of uncontrolled seizures * presence of severe visual disturbances.

Keywords: robotic rehabilitation gait
antimicrobial stewardship in community pharmacy

Conditions: Otitis Media

Summary: acute otitis media (aom) is the most common indication for antibiotics for canadian paediatric patients. as the gatekeepers of safe and effective prescription pharmacotherapy, community pharmacists are well positioned to influence and optimize antibiotic use. the purpose of this project is to develop, implement, and evaluate an antimicrobial stewardship program in the community pharmacy setting that aims to optimize antibiotic use for aom. this nonrandomized pre-post study includes children aged 6 months to 12 years presenting with an antibiotic prescription for aom at two community pharmacies in toronto, ontario. participants are excluded if they exhibit signs/symptoms of mastoiditis, have an additional indication for systemic antibiotics, or parents/guardians cannot consent in english. the multifaceted ams intervention includes pharmacist education, a clinical decision support tool, a parent/guardian questionnaire, and individualized monthly audit and feedback with each pharmacist. prescriptions are reviewed and adapted by the pharmacist to optimize congruence with 2016 canadian paediatric society aom guidelines. the primary outcome is the percentage change in guideline congruence attributable to pharmacist intervention. this study will provide insight into the opportunities and barriers of developing large-scale antimicrobial stewardship programs for community pharmacies.


Eligibility criteria:
inclusion criteria: * prescribed systemic oral antibiotic therapy * antibiotics are indicated for the treatment of acute otitis media (aom) as reported verbally or in writing by parent/guardian or prescriber exclusion criteria: * signs/symptoms of mastoiditis * a diagnosis in addition to aom for which systemic antibiotics are indicated * parents/guardians cannot consent to the study in english

Keywords: antimicrobial stewardship pharmacies community pharmacy services anti-infective agents drug utilization
cystoealstometer (bladder monitor device)-home use

Conditions: Urinary Bladder, Neurogenic

Summary: the investigators have developed a novel pressure monitoring device called a 'cystoelastometer' that connects to a drainage end ofastandard urinary catheters that are used by patients with a neurogenic bladder on daily clean intermittent catheterization. the device has already been demonstrated to be accurate in measuring bladder pressure compared to the gold standard urodynamics that are performed in the clinic or hospital. this study will assess the patients and care givers ability and experience using the cystoelastometer device in a home setting.

: for patients with neurogenic bladder, regular monitoring of bladder pressure and capacity is a critical component of maintaining renal and urinary health. this monitoring is currently done by in-office urodynamics testing (uds). this testing is done intermittently, leaving open the possibility of worsening of bladder function and renal deterioration between testing sessions. this study utilizes a novel pressure and bladder volume monitoring device which is portable and attaches to the end of a standard urinary catheter and measures the pressure in the device and then assists in the drainage of the bladder and records the bladder volume. the investigators will be investigating if this device can be used by patients or their caregivers in a home setting. this study will enroll patients with neurogenic bladder that currently perform clean intermittent catheterization on a daily basis as part of their regular care. the patients will be asked to use the device at least twice a day for two weeks.

Eligibility criteria:
inclusion criteria: * patients seen in the university of iowa pediatric urology clinic with neurogenic bladder managed with clean intermittent catheterization. * patients who haven't had any change in management * patients who had recently had uds (urodynamic study) performed exclusion criteria: * phone which is not ios compatible

Keywords: urodynamics neurogenic bladder
predicting cancer in pancreatic cystic lesions through artificial intelligence

Conditions: Pancreatic Cancer; Pancreatic Cystic Lesions

Summary: this international, multicenter retrospective study aims to develop a deep learning (dl)-based predictive model to identify malignant transformation in pancreatic cystic lesions, improving upon current clinical guidelines. the model will integrate clinical, biochemical, and multimodal imaging data. several 3d convolutional neural networks will be trained using advanced preprocessing, data augmentation, and hybrid fusion techniques. model performance will be compared to that of existing international guidelines. the study involves no additional procedures for patients and adheres to strict data anonymization and privacy regulations.


Eligibility criteria:
inclusion criteria: * patients diagnosed with pcl(s ) who underwent pancreatic surgery in one of the participant centers. surgical indication must adhere to at least one of current guidelines on pcls management (6), based on clinical, biochemical, and radiological (mr and/or eus) features. * pancreatic surgery b83performed for supposed increased risk of cyst(s) malignant degeneration following current guidelines on pcls management (6). * absence of clinical, biochemical, radiological, and anatomopathological evidence of pancreatic cancer at pancreatic surgery. * non-opposition to the anonymous data processing by the included patients. exclusion criteria: * patients presenting with evidence of pancreatic cancer at surgery. * pcl(s) diagnosis and treatment performed without one between eus and pancreatic mr. surgery performed in the absence of the criteria proposed by current guidelines. * unavailability of both preoperative eus and pancreatic mr data. * unavailability of postoperative pcl(s) anatomopathological analysis results. * sbo diagnosis performed without ct-scan.
rituximab plus chemotherapy for cd20+ adult acute lymphoblastic leukemia

Conditions: Acute Lymphoblastic Leukemia

Summary: the main purpose of this study is to evaluate the safety and efficacy of rituximab combined with chemotherapy in cd20+ adult acute lymphoblastic leukemia.

acute lymphoblastic leukemia (all) is a group of biologically heterogeneous diseases with diverse prognosis. novel strategies for adult all have approached a cr rate of over 80%, which is similar to pediatric all. but the long term survival of adult all is only 30%-40%, much lower than pediatric patients. in our trial, all the patients will first receive vincristine 1.4mg/m2, max 2mg iv days 1,8,15,22, daunorubicin 45mg/m2 iv days 1-3,cyclophosphamide 750mg/m2 iv day 1 and prednisone 40-60mg/m2,by mouth days 1-14 (vdcp)regimen as initial induction therapy. if patients achieve complete remission after induction, they will be enrolled in our study for further consolidation and maintenance. if the tumor cells in bone marrow remain 5% to 20% after induction, the patients will receive vdclp(vdcp+l-asparaginase 6000iu/m2 iv days5,7,9,11,13) and be enrolled until complete remission. rituximab is the main experimental intervention in our study.the consolidation regimen is hypercvad/ma or r-hypercvad/ma for totally 8 courses. the maintenance regimen includes 6-mercaptopurine+methotrexate for 24 months, vincristine+prednisone for the first 12 months, l-asparaginase in month 3 and 9 with or without rituximab in month 6 and 12.

Eligibility criteria:
inclusion criteria: * diagnosis of cd20-positive all * adequate liver function (bilirubin less than or equal to 1.5\*uln, unless considered due to tumor), and renal function (creatinine less than or equal to 1.5\*uln, unless considered due to tumor) * signed informed consent exclusion criteria: * prior history of treatment with high-dose ara-c, mtx or rituximab * pregnant or lactating women * history of allergy to rituximab * unable to sign informed consent * active replication of hbv * history of stem cell transplantation

Keywords: rituximab hypercvad
peg-rhg-csf in patients with breast cancer receiving chemotherapy

Conditions: Breast Cancer

Summary: the purpose of this study is to evaluate the efficacy and safety of peg-rhg-csf in patients with breast cancer receiving chemotherapy


Eligibility criteria:
inclusion criteria: * patients with age between 18 and 70 years * diagnosis of breast cancer patients * chemotherapy naive * karnofsky performance status ≥ 70 * written informed consent are acquired exclusion criteria: * uncontrolled infection * have accepted radiotherapy within 4 weeks before anticipated the study * pregnancy * other situations that investigators consider as contra-indication for this study

Keywords: peg-rhg-csf
molecular epidemiology of lymphoma patients

Conditions: Lymphoma

Summary: primary objectives: 1. to enroll and obtain, through questionnaires, risk factor information on all study participants to develop detailed demographic, epidemiologic and behavioral profiles. 2. to assess the influence of relevant epidemiologic covariates such as age, gender, smoking and family history of cancer on the panel of susceptibility biomarkers. 3. to evaluate the role of genomic instability in development of lymphomas.

this study will include individuals diagnosed with lymphoma and individuals with no history of cancer. half of the participants in this study will have lymphoma, and half will have no history of cancer. information from both groups will be compared to help researchers try to learn which factors may lead to the development of lymphoma. if you agree to take part in this study, you will be asked to complete a questionnaire at m. d. anderson. in this questionnaire, you will be asked about your demographics (such as your age, sex, etc.), certain environmental exposures (such as pollution), your medical history, family history, diet, and your past and present smoking and alcohol use habits. this questionnaire should take about 50 minutes to complete. you will also have about 2 ½ tablespoons of blood drawn for special tests. these tests will look for any biologic factors (such as changes in your dna) that may be linked to lymphoma. you will not be informed of the results of any of the testing done with your blood samples. your participation will be over in this study once your blood has been drawn. this is an investigational study. up to 800 participants will take part in this study. all will be enrolled at m. d. anderson.

Eligibility criteria:
inclusion criteria: 1. cases only: newly diagnosed, previously untreated patients with lymphoma as the primary cancer. 2. age 18 years and older. 3. willing to donate 30ml of blood. 4. willing to complete a self-administered questionnaire. 5. controls only: no prior cancer. exclusion criteria: 1. cases only: prior history of cancer other than lymphoma. 2. unable to speak or read english

Keywords: lymphoma epidemiology lifestyle factors questionnaire survey